

Human Papillomavirus Protein E7 (E7) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/H08F5258A80EN.html>

Date: February 2018

Pages: 120

Price: US\$ 3,500.00 (Single User License)

ID: H08F5258A80EN

Abstracts

Human Papillomavirus Protein E7 (E7) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'Human Papillomavirus Protein E7 (E7) - Pipeline Review, H1 2018'; Human Papillomavirus Protein E7 (E7) pipeline Target constitutes close to 39 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes.

Human Papillomavirus Protein E7 (E7) - Human Papilloma Virus (HPV) E7 protein belongs to a group of proteins called oncoproteins. It plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle. E7 protein has both transforming and trans-activating activities. It induces the disassembly of the E2F1 transcription factor from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes.

It interferes with host histone deacetylation mediated by HDAC1 and HDAC2, leading to transcription activation. It plays an important role in the inhibition of both antiviral and antiproliferative functions of host interferon alpha.

The report 'Human Papillomavirus Protein E7 (E7) - Pipeline Review, H1 2018' outlays comprehensive information on the Human Papillomavirus Protein E7 (E7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8, 3, 14 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Anal Cancer, Oropharyngeal Cancer, Hepatocellular Carcinoma, Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Non-Small Cell Lung Carcinoma, Penile Cancer, Rectal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Vaginal Cancer and Vulvar Cancer.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E7 (E7)

The report reviews Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics and enlists all their major and minor projects

The report assesses Human Papillomavirus Protein E7 (E7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA)

and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Human Papillomavirus Protein E7 (E7) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E7 (E7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E7 (E7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Human Papillomavirus Protein E7 (E7) - Overview

Human Papillomavirus Protein E7 (E7) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics
Development

Abion Inc

Advaxis Inc

Bioleaders Corp

BioNTech AG

Cancer Research Technology Ltd

Etubics Corp

Formune SL

Genexine Inc

Hookipa Biotech AG

iBio Inc

Immunovaccine Inc

Inovio Pharmaceuticals Inc

MedImmune LLC

Selecta Biosciences Inc

Touchlight Genetics Ltd

Transgene SA

VLPbio

Human Papillomavirus Protein E7 (E7) - Drug Profiles

ABN-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

axalimogene filolisbac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

axalimogene filolisbac second generation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLSILSB-710c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BVAC-C - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CerviVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUE-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUE-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNA Vaccine to Target E7 for HPV Associated Cancers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPXE-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDA-HPVE7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLBL-101c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-188E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [Serotype 16] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotypes 16] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-3106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-0457 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Vector Vaccine to Target Human Papillomavirus Protein E7 for HPV
Associated Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEL-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TA-CIN - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-4001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tricurin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTFC-E7SH - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target E6 and E7 for Human Papillomavirus (HPV) Associated Cancer -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VGX-3100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vvax-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Human Papillomavirus Protein E7 (E7) - Dormant Products

Human Papillomavirus Protein E7 (E7) - Discontinued Products

Human Papillomavirus Protein E7 (E7) - Product Development Milestones

Featured News & Press Releases

Feb 13, 2018: Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union

Feb 12, 2018: Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer

Jan 29, 2018: Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies

Jan 08, 2018: Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase

Dec 05, 2017: Cue Biopharma Announces Appointment of Colin Sandercock as Senior Vice President and General Counsel

Nov 29, 2017: Inovio's Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy

Nov 27, 2017: Inovio Pharmaceuticals Provides Update on Cancer Drug Candidate INO-3112

Nov 10, 2017: Inovio Pharmaceuticals Presents data on MEDI0457 at Society for Immunotherapy of Cancer Conference

Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers

Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders

Jun 26, 2017: Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017

Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer

Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer

May 18, 2017: Advaxis to Host Investor & Analyst Day on June

May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Abion Inc, H1 2018
Pipeline by Advaxis Inc, H1 2018
Pipeline by Bioleaders Corp, H1 2018
Pipeline by BioNTech AG, H1 2018
Pipeline by Cancer Research Technology Ltd, H1 2018
Pipeline by Etubics Corp, H1 2018
Pipeline by Formune SL, H1 2018
Pipeline by Genexine Inc, H1 2018
Pipeline by Hookipa Biotech AG, H1 2018
Pipeline by iBio Inc, H1 2018
Pipeline by Immunovaccine Inc, H1 2018
Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Pipeline by MedImmune LLC, H1 2018
Pipeline by Selecta Biosciences Inc, H1 2018
Pipeline by Touchlight Genetics Ltd, H1 2018
Pipeline by Transgene SA, H1 2018
Pipeline by VLPbio, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

COMPANIES MENTIONED

Abion Inc

Advaxis Inc

Bioleaders Corp

BioNTech AG

Cancer Research Technology Ltd

Etubics Corp

Formune SL

Genexine Inc

Hookipa Biotech AG

iBio Inc

Immunovaccine Inc

Inovio Pharmaceuticals Inc

MedImmune LLC

Selecta Biosciences Inc

Touchlight Genetics Ltd

Transgene SA

VLPbio

I would like to order

Product name: Human Papillomavirus Protein E7 (E7) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/H08F5258A80EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H08F5258A80EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970